LIPID C24
Formulation & Performance

This edition organizes the previously reviewed, source-linked product record. It is not a new independent review of every paper or supporting file. Reported and calculated values retain their original labels.

Literature-reported formulation composition

Component	mol%	Role
C24	48	Ionizable lipid
DSPC	13	Helper phospholipid
Cholesterol	37	Sterol
DMG-PEG2000	2	PEG lipid
Reported total	100	Source values retained

Component molecular weights and calculated amounts

Composition retained from the cited study below. Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.

Total lipid mass (mg)

Component	Normalized mol%	Amount (µmol)	Weight (mg)
C24	48.000	67.0089	58.6890
DSPC	13.000	18.1482	14.3398
Cholesterol	37.000	51.6527	19.9715
DMG-PEG2000	2.000	2.7920	6.9996

Calculated total: 100.0000 mg lipid.

Calculated catalog planning quantities; RNA, solvent and process loss are excluded. DMG-PEG2000 uses 2507. Component mass = total lipid mass × molar parts × molecular weight / sum(parts × molecular weight). This conversion does not infer N/P.

N/P ratio4

Total lipid:cargo weight ratioNot reported and not inferred.

Buffer & pHPBS pH 7.4 during collection and dilution; final dialysis to pH 7.3-7.4.

CargoFirefly-luciferase mRNA or SARS-CoV-2 S2P mRNA, according to experiment

Administration routeIntramuscular

DoseReporter studies: 0.5 or 5 micrograms mRNA. Immunogenicity/challenge: 0.1, 0.25, 0.5 or 1 microgram S2P mRNA.

Animal modelBALB/c mice and K18-hACE2 mice

Formulation processLipids in ethanol and mRNA in aqueous buffer were mixed with a Spark NanoAssemblr. The dispersion was ejected into PBS, diluted 1:1 with PBS and dialyzed with six buffer exchanges over 6 h using a 10 kDa device. Exact stream flow rates were not reported.

Literature-reported performance for the cited formulation

Literature-reportedTNS apparent pKa6.77C24 LNP; MC3 comparator 6.55PDF Results and Fig. 1

Literature-reportedZeta-potential fit pKa / isoelectric point5.21 / 6.12Separate electrokinetic titration; not interchangeable with TNS pKaPDF Results and Fig. 1

Literature-reportedRiboGreen-inaccessible mRNA68%C24 LNP; MC3 79%; not labeled as definitive EEPDF Results and Fig. 1

Literature-reportedMuscle luciferase expressionApproximately 4-fold MC30.5 microgram mRNA IM; 4 hPDF Results and Fig. 2

Literature-reportedPseudovirus neutralizationApproximately 10-fold MC3 after boost0.25-1 microgram S2P mRNA dosesPDF Results and Fig. 4

Literature-reportedChallenge protection3/3 followed mice survived at 0.25 microgramK18-hACE2; initial n=5, two animals/group used for day-5 lung titersPDF Fig. 5 legend

Selected C24 study findings

Experiment	Condition	Reported result
Reporter expression	0.5 microgram mRNA IM; 4 h	Approximately 4-fold MC3 at muscle
Local histology	5 micrograms mRNA; 24 h; n=3	Less injection-site inflammation than MC3 in this study
K18-hACE2 challenge	0.25 microgram S2P; survival n=3	3/3 followed mice survived
Short-term storage	PBS; 14 days	Bioactivity stable at 4 C; 20-40% decrease at room temperature

Preprint Figs. 2-6 and supplementary stability figures.

Additional reported findings

Liver off-target reporter signal

At 5 micrograms mRNA, liver signal was reported as approximately sixfold lower than MC3 (p=0.051).

BALB/c IM reporter study · PDF Results and Fig. 2

Lung viral titers

C24 at 0.5 microgram eliminated detectable lung infection in the two animals assessed on day 5; MC3 did not completely eliminate infection even at 1 microgram.

K18-hACE2 challenge; n=2 for lung titers · PDF Fig. 5

RNA integrity

mRNA integrity was retained for at least 19 days at 4 C and declined more slowly for C24 than MC3 at higher storage temperatures.

Study formulation in PBS · Supplementary stability figures

Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.

Cited literature for this formulation and performance datasetAlishetty S, et al. Novel lipid nanoparticle provides potent SARS-CoV-2 mRNA vaccine at low dose with low local reactogenicity, high thermostability and limited systemic biodistribution. Research Square. 2021. DOI: 10.21203/rs.3.rs-798453/v1
All formulation and performance claims are restricted to the reported C24 formulations and stated experimental conditions.